| Date | Title | Description |
| 17.04.2025 | A New Dawn in Pediatric Health: Ziresovir's Breakthrough Against RSV | In the world of pediatric medicine, a storm brews. Respiratory syncytial virus (RSV) is a formidable foe, striking down infants and young children with relentless ferocity. Each year, millions of cases emerge, leading to countless hospitali... |
| 16.04.2025 | The Lancet Child & Adolescent Health Publishes Phase III Trial and 24-Month Follow-Up Results of Ziresovir for RSV in Infants Under 6 Months | SHANGHAI, April 16, 2025 /PRNewswire/ -- The Lancet Child & Adolescent Health, a leading international journal in pediatric and adolescent medicine, has published the Phase III clinical trial results of ziresovir, a novel RSV-targeted a... |
| 24.03.2025 | Sermonix and Regor Announce Strategic Collaboration to Optimize Regor's Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics | Partnership aims to develop efficacious and well-tolerated treatments for advanced metastatic breast cancer
COLUMBUS, Ohio, and CAMBRIDGE, Mass., March 24, 2025 /PRNewswire/ -- Sermonix Pharmaceuticals, a privately held biopharmaceutical co... |
| 18.03.2025 | InOrbit Space Intelligence™ Advances Physical AI Powered by NVIDIA to Optimize Industrial Workflows | InOrbit Space Intelligence and NVIDIA Simulation Technologies, Orchestrating the Future of Robotics
InOrbit.AI is advancing Physical AI to optimize industrial robot operations, leveraging NVIDIA's advanced simulation technology, enabling th... |
| 12.03.2025 | Fusion Fund: $190 Million In Committed Capital Raised For Fund IV | With $190 million in committed capital, Fusion Fund has announced the closing of Fusion Fund IV to continue supporting technical founders in enterprise AI, healthcare, and industrial automation. And Fund IV was oversubscribed in less than s... |
| 09.03.2025 | Navigating the New Normal: The Impact of Menopause on Women in the Workplace | Menopause is a natural phase of life, yet it remains shrouded in silence. For many women, this transition is a stormy sea of symptoms that can disrupt both personal and professional lives. The conversation around menopause is finally gainin... |
| 07.03.2025 | Health | More than hot flashes: Women raise awareness about menopause symptoms and work | The many manifestations include insomnia, migraines, brain fog, loss of concentration, memory problems, mood swings, depression, anxiety, heart palpitations, hair loss and weight gain. If that wasn’t enough, some people experience heavy, pa... |
| 30.01.2025 | Roche Pharma appoints new India head | Roche Pharma India has appointed Rajwinder Mehdwan as country General Manager, effective 1 April 2025.
She will also join the leadership team of the Central Eastern Europe, Turkey, Russia and Indian subcontinent region (CEETRIS), reporting ... |
| 29.01.2025 | Atalanta Therapeutics: A New Dawn in Neurological Treatments | Atalanta Therapeutics is making waves in the biotech ocean. This Boston-based company has just secured $75 million in Series B funding, a lifeline for its ambitious plans to tackle neurological diseases. The funding round was led by EQT Lif... |
| 29.01.2025 | Prevent Blindness Declares February as Age-related Macular Degeneration and Low Vision Awareness Month to Educate Public on the Eye Disease and Available Support Programs | February declared as Age-related Macular Degeneration (AMD) and Low Vision Awareness Month by Prevent Blindness to educate public on one of the leading causes of vision loss.
Prevent Blindness provides a wealth of free educational resources... |
| 28.01.2025 | EQT Life Sciences leads USD 97 million Series B in Atalanta Therapeutics, a biotech firm developing treatments for epilepsy and Huntington’s disease | EQT Life Sciences leads USD 97 million Series B in Atalanta Therapeutics, a biotech firm developing treatments for epilepsy and Huntington’s disease
Tue, Jan 28, 2025 13:00 CET Report this content
Atalanta Therapeutics is pioneering RNA int... |
| 25.01.2025 | Andhra Pradesh's Bold Bid for Swiss Investment: A New Economic Horizon | Andhra Pradesh is casting its net wide. The state is on a mission to attract Swiss investments in research and development (R&D) and manufacturing. This is not just a call for funds; it’s a strategic move to reshape its economic landsca... |
| 24.01.2025 | Nuevocor Welcomes Andreas Wallnöfer as Chairman of the Board of Directors | SINGAPORE and PHILADELPHIA, Jan. 24, 2025 /PRNewswire/ -- Nuevocor, an IND-stage biotechnology company dedicated to developing functional cures to treat cardiomyopathies with aberrant mechanobiology, today announces the appointment of Dr. A... |
| 11.01.2025 | Regor Releases Phase 2a Topline Results for RGT-075, an Oral Once-daily Small Molecule GLP-1R Agonist, and Begins Phase 2b Study in the US for the Treatment of Obesity | Regor announced its 12-week single-dose Phase 2a trial results for RGT-075, a once-daily oral GLP-1RA, reporting 5% placebo-adjusted weight-loss with no plateau
No treatment-related severe adverse events (AEs), with only 4% discontinuation ... |
| 10.01.2025 | Hippocratic AI valued at $1.64 billion after series B round | iStock
Hippocratic AI notched a valuation of $1.64 billion after its latest fund raise led by Kleiner Perkins, the VC firm that backed Google, Amazon, and Genentech as AI funding thrives.
Read More News on
artificial intelligenceHippocratic... |
| 10.01.2025 | Hippocratic AI valued at $1.64 billion after series B round | (Corrects amount raised to $141 million from $126 million in paragraph 2)
:Hippocratic AI notched a valuation of $1.64 billion after its latest fund raise led by Kleiner Perkins, the VC firm that backed Google, Amazon, and Genentech as AI f... |
| 06.01.2025 | General Proximity Raises $16M in Funding | General Proximity, a San Francisco, CA-based biotech platform company, raised $16M in funding.
The round was led by Aydin Senkut at Felicis. Other investors included Y Combinator, age1, Modi Ventures, Wilson Sonsini, as well as a number of ... |
| 20.12.2024 | Ottimo Pharma: A New Dawn in Cancer Treatment with $140 Million Boost | In the world of biotechnology, every dollar counts. Ottimo Pharma, a New York City-based biotech firm, has just raised over $140 million in a Series A funding round. This infusion of capital is not just a financial milestone; it’s a beacon ... |
| 20.12.2024 | Ottimo Pharma: Over $140 Million (Series A) Raised To Advance Bifunctional Medicines | Ottimo Pharma – a private biotech company pioneering bifunctional medicines to extend the lives of people with cancer – announced the completion of a Series A financing round of over $140 million. The funding round was led by OrbiMed, Avoro... |
| 09.12.2024 | 2024 ESMO Asia: TransThera announces clinical data of tinengotinib in combination with atezolizumab (PD-L1) in biliary tract carcinoma (BTC) | NANJING, China and GAITHERSBURG, Md., Dec. 9, 2024 /PRNewswire/ -- TransThera Sciences Nanjing, Inc. (the "TransThera") announced the poster presentation at the 2024 European Society For Medical Oncology (ESMO) Asia Congress to di... |
| 07.12.2024 | Для предотвращения деменции оказались важны только три этих фактора | Отсутствие хобби, ожирение и малоподвижный образ жизни после 60 лет названы главными факторами, влияющими на развитие этого расстройства, пишет Daily Mail. Таким образом, вязание, регулярные прогулки и контроль за потреблением калорий являю... |
| 26.11.2024 | ArkBio's Breakthrough in RSV Prevention: A New Hope for Vulnerable Infants | In the world of medicine, every breakthrough is a beacon of hope. Ark Biopharmaceutical Co., Ltd. (ArkBio) has recently illuminated the path forward with its Phase 1 clinical study of AK0610, a monoclonal antibody aimed at preventing respir... |
| 26.11.2024 | The Race Against Obesity and RSV: Innovations in Biotech | In the world of biotechnology, two companies are racing to tackle pressing health issues: obesity and respiratory syncytial virus (RSV). Pep2Tango Therapeutics and ArkBio are making strides that could change the landscape of treatment for m... |
| 25.11.2024 | ArkBio Announces Successful Completion of Enrollment and Dosing for Phase 1 Clinical Study of AK0610, a Preventive Antibody Against Respiratory Syncytial Virus Infection | SHANGHAI, Nov. 25, 2024 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") announced today the successful enrollment and dosing of all participants in a Phase 1 clinical study of AK0610, a fully human monoclonal a... |
| 09.11.2024 | The Future of Weight Loss: Ascletis' ASC47 and Tezspire's Breakthrough in Nasal Polyps | In the ever-evolving landscape of pharmaceuticals, two recent studies shine a light on innovative treatments that could reshape how we approach obesity and chronic rhinosinusitis with nasal polyps. Ascletis Pharma's ASC47 and AstraZeneca's ... |
| 08.11.2024 | Tezspire nasal polyps trial met primary endpoints | Tezspire nasal polyps trial met primary endpoints
Fri, Nov 08, 2024 08:00 CET Report this content
08 November 2024
Tezspire met both co-primary endpoints in the Phase III WAYPOINT trial in patients
with chronic rhinosinusitis with nasal pol... |
| 28.10.2024 | Be Biopharma: Pioneering the Future of Genetic Medicine with $82 Million in New Funding | In the ever-evolving landscape of biotechnology, Be Biopharma stands out like a lighthouse in a storm. This Cambridge, Massachusetts-based company has just secured $82 million in funding, a financial windfall that promises to propel its inn... |
| 25.10.2024 | Be Bio: $82 Million Raised To Discover And Develop Engineered B Cell Medicines | Be Biopharma – a leader in the discovery and development of engineered B Cell Medicines (BCMs) – announced key milestones alongside a new round of funding as its lead program BE-101 for Hemophilia B, enters the clinic, and its second develo... |
| 30.09.2024 | Regor Enters into a Definitive Purchase Agreement for Genentech to Acquire Regor's Portfolio of next-generation CDK inhibitors for the Treatment of Breast Cancer | Genentech will acquire Regor's next-generation CDK inhibitors for an upfront payment of $850 million in cash. Regor is also eligible to receive additional cash payments contingent on achieving future development, regulatory and commercial m... |
| 30.09.2024 | PeriVision in the fast lane |
Since the FDA registration of its first medical software VisionOne, everything has accelerated for PeriVision. In line with its plans, this summer the Swiss eye care start-up signed a distribution agreement with Von Hoff, one of the leadin... |
| 26.09.2024 | Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis | Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis The REGENCY study met its primary endpoint, demonstrating statistically significant and clinically meaningful t... |
| 16.09.2024 | Circle Pharma Expands Leadership Team to Drive the Development of Its Pipeline of Oral Macrocycle Therapies | SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–September 16, 2024–
Circle Pharma, Inc., a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class of therapies, today announced ... |
| 13.09.2024 | FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy | Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous
(IV) Tecentriq1,2New subcutaneous (SC) option reduces treatment time to approxima... |
| 13.09.2024 | FDA Roundup: September 13, 2024 | SILVER SPRING, Md., Sept. 13, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:
On Thursday, the FDA published the FDA Voices: "Join FDA for the First ... |
| 05.09.2024 | Health | The technology used to make the COVID vaccine may be key to pancreatic cancer treatment | Once removed, the tumor is sent to a company in Europe, Genentech, which will perform DNA sequencing on the tumor to create an individualized vaccine for each patient. If effective, the vaccine will lessen the recurrence of pancreatic cance... |
| 03.09.2024 | SKIES ACROSS NORTH AMERICA TO LIGHT UP THIS FALL IN SUPPORT OF BLOOD CANCER PATIENTS | The Leukemia & Lymphoma Society kicks off philanthropic campaign Light The Night; communities nationwide encouraged to learn why awareness and support is critical
RYE BROOK, N.Y., Sept. 3, 2024 /PRNewswire/ -- The Leukemia & Lymphom... |
| 29.08.2024 | Navigating the New Normal: COVID Vaccines and Creative Leadership in Healthcare | The landscape of healthcare marketing is shifting. Imre, a prominent brand engagement agency, has made significant strides by appointing Tracy Zuto and Malia Baker as key creative leaders. Their arrival signals a commitment to innovative, i... |
| 28.08.2024 | Imre announced two new appointments to Strengthen Brand AOR Expertise | Imre continues its commitment to cutting-edge creative that builds brand engagement with the appointment of two senior creative leaders, as the agency strengthens its position as a distinct choice for agency-of-record assignments in healthc... |
| 27.08.2024 | Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH | With the option to self-administer, PiaSky® (crovalimab) has the potential to reduce treatment burden for people with paroxysmal nocturnal haemoglobinuria (PNH) in Europe and their caregiversApproval is based on COMMODORE 2, where subcutane... |
| 27.08.2024 | ArkBio Presented at the 8th Annual IPF Summit and Announced Completion of Patient Enrollment for Phase 2 Clinical Trial of AK3280, a Next-Generation Drug for IPF Treatment | BEIJING, Aug. 27, 2024 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio"), a privately held, clinical-stage biopharmaceutical company today announced that Dr. Jim Wu, Chief Executive Officer of ArkBio, gave an ora... |
| 27.08.2024 | Imre Appoints Powerhouse Leaders Tracy Zuto and Malia Baker and Strengthens Brand AOR Expertise | New Additions Reflect Commitment to Creative Excellence and Healthcare Industry Leadership
NEW YORK, Aug. 27, 2024 /PRNewswire/ -- Imre continues its commitment to cutting-edge creative that builds brand engagement with the appointment of t... |
| 22.08.2024 | Global Genes' Annual Week in RARE Event Heading to Kansas City | Global Genes
Global Genes is taking Week In RARE on the road to Kansas City, after having hosted this annual event in California for over 12 years. Moving the location annually will help make the event more accessible and equitable to the g... |
| 21.08.2024 | Innovations in Financial Planning: A New Era for Later Life Management | In the world of finance, innovation is the lifeblood that keeps the industry vibrant. Recently, two companies emerged as champions in the Later Life Financial Planning Innovation Challenge, hosted by Smart Data Foundry and FinTech Scotland.... |
| 20.08.2024 | REPUBLICA HAVAS EXPANDS NORTH AMERICAN FOOTPRINT WITH THREE APPOINTMENTS | A trio of executives has been appointed to lead the agency's expansion into New York City
NEW YORK, Aug. 20, 2024 /PRNewswire/ - Republica Havas announced today the appointments of three executives to lead the agency's continued expansion i... |
| 17.08.2024 | KNIME: Open-Source Data Science And AI Company Raises $30 Million | KNIME, one of the leading open-source data science and AI companies, announced it has raised additional funding from its longstanding investor, Invus. Since the last announcement, Invus has invested another $30 million, bringing the total f... |
| 15.08.2024 | Invus invests additional $30M in Knime |
KNIME helps everybody make sense of data. Its free and open-source KNIME Analytics Platform enables anyone – from business to technical and data backgrounds – to intuitively work with data. KNIME Hub is the commercial complement to KNIME A... |
| 13.08.2024 | Takeda, Roche, and Genentech Recognized by the Healthcare Businesswomen's Association for Advancing Women in the Workplace Initiatives | UCB Transformational Program Also Honored
FAIRFIELD, N.J., Aug. 13, 2024 /PRNewswire/ -- To showcase the impactful commitment and outcomes of equitable practices for women in the workplace, the Healthcare Businesswomen's Association (HBA) t... |
| 07.08.2024 | KNIME's Bold Leap into the Future of AI Governance | In the fast-paced world of artificial intelligence, the race is on. Companies are scrambling to harness the power of AI while managing its risks. KNIME, a leader in open-source data science, has just made a significant move. The company sec... |
| 06.08.2024 | KNIME Secures Investment to Accelerate Enterprise AI Governance and ModelOps | KNIME, one of the leading open-source data science and AI companies, has raised additional funding from its longstanding investor Invus. Since the last announcement, Invus invested another $30M, bringing total funding to $50M. This will all... |
| 06.08.2024 | Open-source data science platform Knime raises $30M to seize opportunity in generative AI
Your vote of support is important to us and it helps us keep the content FREE.
One click below supports our mi... | Open-source data science platform provider Knime AG said today it has closed on a new, $30 million investment from its longtime backer Invus.
The round is the first major investment the company has received since Invus led its initial Serie... |
| 05.08.2024 | SITC Announces 2024 Class of Fellows to the Academy of Immuno-Oncology | Academy of Immuno-Oncology
The Society for Immunotherapy of Cancer (SITC) announces the 2024 Class of Fellows of the Academy of Immuno-Oncology (FAIO). The luminaries of the 2024 class will be inducted at an event during SITC's 39th Annual ... |
| 01.08.2024 | Curis Provides Second Quarter 2024 Financial and Operating Update | EC Grants ODD to emavusertib in PCNSL
Management to host conference call and webcast today at 8:30 a.m. ET
LEXINGTON, Mass., Aug. 1, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emav... |
| 30.07.2024 | European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO) | Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept, and robust retinal drying with VabysmoAdditional submitted ... |
| 29.07.2024 | Predicta Biosciences: Pioneering a New Era in Cancer Diagnostics | Predicta Biosciences is making waves in the ocean of cancer diagnostics. With a fresh infusion of $5.2 million in seed funding, this Boston-based precision oncology company is poised to change the landscape of how we detect and treat blood ... |
| 29.07.2024 | Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care | The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances.LumiraDx’s transformative Point of Care solution will complement Roche’s diagnostics portfolio across Clinical Chemistry, Immun... |
| 27.07.2024 | The Future of Diagnostics: Roche's Vision Unveiled at ADLM 2024 | In the bustling heart of Chicago, Roche is setting the stage for the future of laboratory diagnostics. At the 2024 Association for Diagnostics & Laboratory Medicine (ADLM) Clinical Lab Expo, the company is showcasing a suite of innovati... |
| 27.07.2024 | The Future of Brain Health: Innovations and Leadership in Alzheimer's and Multiple Sclerosis Treatments | In the ever-evolving landscape of biotechnology, two companies are making waves in the treatment of chronic neurological diseases: Immunic, Inc. and Neurophet. Both are leveraging advanced technologies and seasoned leadership to tackle the ... |
| 27.07.2024 | Predicta Biosciences Raises $5.2 Million To Develop Novel Diagnostic And Therapeutic Products | Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic products, announced it had raised an oversubscribed $5.2 million seed round led by The Engine Ventures. And additional participating investors in... |
| 25.07.2024 | [Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised | Group sales were up by 5%1 at constant exchange rates (CER) (stable in CHF) in the first half, driven by the high demand for both our medicines and diagnostics; excluding COVID-19-related products, sales increased by 8%
Group sales growth a... |
| 25.07.2024 | Arizona Retina Surgeon Performs First FDA Approved Procedure in the U.S. That Eliminates Monthly Eye Injections for Wet AMD | Dr. Graff and Surgical Staff - First FDA-Approved Procedure in the U.S. using Susvimo® That Eliminates Monthly Eye Injections for Wet AMD
New Wet Age-Related Macular Degeneration (AMD) treatment available at Barnet Dulaney Perkins Eye Cente... |
| 25.07.2024 | Roche showcases solutions for laboratories of the future at the Association for Diagnostics & Laboratory Medicine 2024 Clinical Lab Expo | Roche will unveil the next generation of core lab and molecular systems, including a total solution for clinical mass spectrometry.
Attendees can experience firsthand how fully integrated systems and data solutions can streamline lab operat... |
| 24.07.2024 | Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec | – Senior Executive and Thought Leader in Brain Health with Nearly Three Decades of Global Pharmaceutical Experience –
– Served as Neuroimmunology Franchise Head Responsible for Roche's Blockbuster Launch of Multiple Sclerosis Therapy Ocrevu... |
| 23.07.2024 | Cleo's Family Health Index™ Achieves Validation from Validation Institute, Enabling Employers to Better Measure the Impact of Offering Parenting & Caregiving Benefits | Cleo's Family Health Index™ (FHI) has been validated by Validation Institute
Validation Institute finds that Cleo, the leading global comprehensive family care platform, accurately measures and assesses employee caregiver health — and there... |
| 22.07.2024 | Society for Immunotherapy of Cancer Announces Annual Award Recipients | Society for Immunotherapy of Cancer logo
The Society for Immunotherapy of Cancer (SITC) honors notable contributors to the cancer immunotherapy field each year. SITC is thrilled to announce its 2024 Annual Awards recipients who will be hono... |
| 10.07.2024 | BOLDEN THERAPEUTICS TO PRESENT AT THE 4TH ANNUAL OLIGONUCLEOTIDES FOR CNS SUMMIT | PROVIDENCE, R.I., July 10, 2024 /PRNewswire/ -- Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote neurogenesis for the potential treatment of CNS illnesses, today announced their invitation... |
| 09.07.2024 | Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes | The Accu-Chek® SmartGuide CGM solution provides 14 days of accurate1 real-time glucose values for adults living with type 1 and type 2 diabetes on flexible insulin therapy.The built-in AI-trained algorithms will empower users to proactively... |
| 08.07.2024 | Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD) | The FDA has approved updates to Susvimo, which will be available to US retina specialists and patients with nAMD in the coming weeksSusvimo offers the first alternative to regular eye injections that are standard of care for nAMD, which imp... |
| 28.06.2024 | CHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition | If approved, PiaSky will be the first monthly subcutaneous (SC) treatment for paroxysmal nocturnal haemoglobinuria (PNH) in the EU Additionally, with the option to self-administer, PiaSky may provide an alternative to existing intravenous (... |
| 28.06.2024 | Roche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO) | Positive recommendation is based on two Phase III studies. In addition to robust retinal drying with Vabysmo, these data show early and sustained vision improvements, which are non-inferior to aflibercept If approved, Vabysmo would be the f... |
| 25.06.2024 | Black and Hispanic Patients Face Higher Liver Cancer ED Visits, Study Finds | What You Should Know:
– A new study by Inovalon, a leader in healthcare data analytics, sheds light on racial and socioeconomic disparities in emergency department (ED) visits for patients with hepatocellular carcinoma (HCC), the most commo... |
| 24.06.2024 | Roche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories | The cobas® c 703 and cobas® ISE neo analytical units, deliver higher testing capacity and increased automation helping to improve laboratory workflows and advance patient care.The new cobas c 703 analytical unit offers industry-leading high... |
| 20.06.2024 | Roche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma | The VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay is the first clinically approved in-situ hybridisation (ISH) test with the sensitivity to assess the full spectrum of B-cell lymphoma subtypes.1,2The test helps differentiate a... |
| 15.06.2024 | Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma | The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with Columvi plus chemotherapy1
This Columvi combinat... |
| 12.06.2024 | Инсулин. Как ГМО спасает миллионы жизней | Инсулин, незаменимый медикамент для 4,6-9 миллионов россиян, по официальным данным. Уже почти 50 лет, благодаря технологиям редактирования генома, он доступен практически каждому диабетику. И позволяет им жить практически нормальной жизнью.... |
| 11.06.2024 | QurAlis Expands Leadership Team With Doug Williamson, M.D., as Chief Medical Officer and Jason Brown, MBA, as Chief Financial Officer and Appoints Shafique Virani, M.D., to Board of Directors | Industry veteran Williamson brings nearly three decades' experience as a leader in neuroscience R&D at organizations including Eli Lilly and Company, Lundbeck, Parexel, and Acadia Pharmaceuticals
Former Karuna CFO Brown brings more than... |
| 10.06.2024 | European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer | European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people ... |
| 10.06.2024 | Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization | The test uses highly sensitive PCR technology, requiring only a single nasal-swab sample to provide rapid, accurate qualitative detection and differentiation among four of the most prevalent respiratory viruses for which differential diagno... |
| 03.06.2024 | Bio-Thera Solutions Receives Positive CHMP Opinion for Avzivi® (bevacizumab), a Biosimilar Referencing Avastin® | CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing Avzivi® to the reference product Avastin®
GUANGZHOU, China, June 3, 2024 /PRNewswire/ -- Bio-Thera Solutions Inc. (688177:SH), a commerc... |
| 23.05.2024 | Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement | SYDNEY, May 23, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) (Kazia or the company) received a letter on May 22, 2024 from Nasdaq notifying the Company that, while the Company has not regained compliance with the Minimum B... |
| 20.05.2024 | SynBioBeta 2024: From novel hosts to ‘tricking’ cells to be more productive… addressing the ‘scale-cost paradox’ in biomanufacturing | Since insulin produced by genetically engineered bacteria—rather than the pancreases of slaughtered animals—was first approved in 1982, the market for ‘biomanufactured’ products produced by microbial, animal, or plant cells has grown rapidl... |
| 18.05.2024 | Детская деменция: что о ней известно, как она возникает и можно ли ее вылечить | «Детство» и «деменция» — два слова, которые не хочется употреблять вместе. Но только в Австралии около 1,4 тыс. детей и подростков живут с детским слабоумием, которое не поддается лечению. Хотя причины этого заболевания отличаются от деменц... |
| 16.05.2024 | Learning culture fosters business success, per this Houston expert | Employee training is often seen as synonymous with learning and development, but there are significant differences. Understanding the differences can help elevate your organization’s programs and foster a learning culture.
Training teaches ... |
| 07.05.2024 | Prevent Blindness to Host the 2024 ASPECT Patient Engagement and Advocacy Summit in Washington, D.C. | Prevent Blindness to host the 2024 ASPECT Patient Engagement and Advocacy Summit and Eyes on Capitol Hill event in Washington, D.C., May 14-16, 2024.
Three-day event brings together patients, care partners, and public health champions to ad... |
| 21.03.2024 | PocketHealth secures $33M for patient-facing medical records platform | Photo: Luis Alvarez/Getty Images
PocketHealth, a platform that enables patients to access their medical imaging, announced it secured $33 million in an all-equity Series B funding round led by Round13 Capital.
Deloitte Ventures participated... |
| 20.03.2024 | Health for All Innovator Sylvie Leotin to Give Keynote Address at the National Institutes of Health Clinical Center | Sylvie Leotin, CEO Equify Health
Sylvie Leotin
Leotin to speak on humanizing healthcare disparities. She founded Equify Health after surviving cancer to improve healthcare delivery for everyone.
If we want to achieve health equity, we need ... |
| 11.03.2024 | Ribometrix to Present New Preclinical Data From RNA-Modulating Small Molecule Programs Targeting eIF4E and c-MYC at the 2024 AACR Annual Meeting | — Data demonstrate in vivo tumor regression via RNA-binding protein inhibitor targeting eIF4E in multiple tumor types with significant unmet need —
— First data disclosure from the Company’s RNA-targeting small molecule platform and its pro... |
| 06.03.2024 | Global Bevacizumab Biosimilars Market Outlook 2024-2028 & 2033 Featuring Cipla, Reliance Lifesciences, Genentech, Fujifilm Kyowa Kirin Biologics, and Pfizer | - |
| 04.03.2024 | Head and Neck Cancer Market Size, Trends, Industry Statistics and Latest Insights Till 2034 | BROOKLYN, NY, USA, March 4, 2024 /EINPresswire.com/ -- What is the market for head and neck cancer?
The head and neck cancer market reached a value of US$ 3,252.3 Million in 2023 and expected to reach US$ 7,279.8 Million by 2034, exhibiting... |
| 21.11.2023 | Genentech, NVIDIA Partner to Revolutionize Drug Discovery with AI | What You Should Know:
– Genentech and NVIDIA today announced a multi-year strategic research collaboration that couples Genentech’s artificial intelligence (AI) capabilities, extensive biological and molecular datasets, and research experti... |
| 21.11.2023 | Nvidia collaborates with Genentech to accelerate AI-driven drug discovery | Are you ready to bring more awareness to your brand? Consider becoming a sponsor for The AI Impact Tour. Learn more about the opportunities here.
Nvidia is working with Roche Group’s Genentech to help the company pioneer the use of generati... |
| 17.08.2023 | The 30 young leaders who are forging a new future for the healthcare industry in 2023 | Your browser does not support the video element. This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
A new generation of leaders is transforming the healthcare industry.
They're developing ne... |
| 20.07.2023 | Stanford president resigns following research ethics probe | The president of Stanford University has stepped down in the wake of an independent investigation that found “substandard practices” in research papers he was involved in.
Marc Tessier-Lavigne, the leader of the prestigious California unive... |
| 27.06.2023 | Nvidia backs Flywheel in $54M round to accelerate medical AI development | Join top executives in San Francisco on July 11-12, to hear how leaders are integrating and optimizing AI investments for success. Learn More
Hours after teaming up with data cloud major Snowflake, Nvidia has backed a vendor working to over... |
| 27.06.2023 | Rare Disease Patient Advocates Gather in San Diego for a Week of Events to Connect, Learn, and Empower | Week in RARE events "We are creating an unparalleled opportunity for rare disease advocates to engage with each other, build relationships, and help them understand what they can do to change what it means to live with a rare disease d... |
| 08.06.2023 | Letter of Support (LOS) Initiative | Critical Path Institute's (C-Path) Predictive Safety Testing Consortium (PSTC), Nephrotoxicity Working Group (NWG) Urinary Biomarkers: Osteopontin and Neutrophil Gelatinase-associated Lipocalin (NGAL) Early Clinical Drug Development 8/20/20... |
| 01.06.2023 | Top AI researcher dismisses AI ‘extinction’ fears, challenges ‘hero scientist’ narrative | Join top executives in San Francisco on July 11-12, to hear how leaders are integrating and optimizing AI investments for success. Learn More
Kyunghyun Cho, a prominent AI researcher and an associate professor at New York University, has ex... |
| 31.05.2023 | Equify Health Receives $1 Million Grant to Launch Transformative Education Workshop to Accelerate Health Care Equity | "Current diversity training doesn’t focus on the patient experience. That’s what makes our workshop unique. We allow medical providers to see firsthand what marginalized patients go through and discover for themselves how health care f... |
| 06.04.2023 | Genentech review of Tessier-Lavigne paper finds no evidence of fraud — but hints at a different misconduct case | South San Francisco biotech Genentech on Thursday announced that an internal review of misconduct allegations concerning a landmark 2009 paper co-authored by Marc Tessier-Lavigne, a former top executive at the company and Stanford Universit... |
| 15.02.2023 | Mindful Life Project raises $1.65 million to address America’s youth mental health crisis by expanding its innovative model in California schools | Students practice mindfulness in school. “Schools become places of belonging, compassion, and wellness when students and educators practice mindfulness, which in turn creates a strong foundation that prioritizes mental health,” says Mindful... |
| 09.01.2023 | Healthcare Hires of Note | ProofPilot, a digital protocol automation platform for clinical trials, has added Bernadette Tosti to its executive leadership team in the role of chief product officer this week. Tosti has more than 15 years of experience in the digital cl... |
